论文部分内容阅读
1975年以来,国内对硝硫氰胺(代号“7505”)的大量实验室与临床研究工作已取得一定成果,但也发现部分病例出现黄疸及肝损害等副作用。为了提高疗效,减轻肝脏和中枢神经系统等副作用,我院研究合成了硝硫苯酯(phenithionate)。经临床前药理实验后,1980年10月在四川治疗463例慢性血吸虫病患者,治疗后6月累积粪便孵化阴转率为79.3％,其中总剂量为26mg/kg组中,6月累积阴转率为85.4％,副作用亦较湖北报告的硝硫氰胺者为轻。 为了扩大治疗,并与硝硫氰胺进行临床对比,于1981年12月又在四川省广汉、绵
Since 1975, a great deal of laboratory and clinical research on nitromethane (codenamed “7505”) has made some achievements in China, but some side effects such as jaundice and liver damage have also been found. In order to improve the curative effect and relieve the side effects such as liver and central nervous system, our institute has synthesized and synthesized phenithionate. After preclinical pharmacological experiments, 463 patients with chronic schistosomiasis were treated in Sichuan in Oct. 1980, and the accumulative feces negative conversion rate was 79.3% after 6 months of treatment, in which the total dose was 26mg / kg, and the cumulative negative conversion in June The rate was 85.4%. Side effects were also lower than those reported by Hubei Province. In order to expand the treatment, and clinically compared with nitrofurazone, in December 1981 in Guanghan, Sichuan Province, cotton